Navigation Links
Nutraceutical Reports Fiscal 2009 Q2 Results
Date:4/30/2009

PARK CITY, Utah, April 30 /PRNewswire-FirstCall/ -- Nutraceutical International Corporation (Nasdaq: NUTR) today reported results for the fiscal 2009 second quarter ended March 31, 2009. Net sales for the fiscal 2009 second quarter were $42.0 million compared to $44.4 million for the same quarter of fiscal 2008.

Primarily as a result of the ongoing U.S. and global economic recession and the related turmoil in the equity markets, there has been a significant and prolonged decrease in the Company's stock price and related market capitalization over the past six months. The ongoing economic recession also has negatively impacted the Company during this period, both domestically and internationally. Based on these factors, the Company determined that an interim goodwill impairment analysis was necessary and performed this goodwill impairment analysis on each of its reporting units during the second quarter of fiscal 2009 in accordance with Statement of Financial Accounting Standards No. 142, Goodwill and Other Intangible Assets. Based on the results of this goodwill impairment analysis, a non-cash goodwill impairment charge of $37.5 million ($27.3 million after tax, or $2.51 per diluted share) was recorded during the second quarter of fiscal 2009.

This non-cash goodwill impairment charge resulted in a net loss of $(23.4) million, or $(2.15) per diluted share, for the second quarter of fiscal 2009, compared to net income of $4.4 million, or $0.39 per diluted share, for the same quarter of fiscal 2008. Excluding the above non-cash impairment charge, net income for the second quarter of fiscal 2009 would have been $3.9 million, or $0.36 per diluted share.

Net sales for the six months ended March 31, 2009 were $81.6 million compared to $85.5 million for the same period in fiscal 2008. The non-cash goodwill impairment charge resulted in a net loss of $(20.2) million, or $(1.86) per diluted share, for the six months ended March 31, 2009, compared to net income of $7.6 million, or $0.67 per diluted share, for the same period of fiscal 2008. Excluding the above non-cash impairment charge, net income for the six months ended March 31, 2009 would have been $7.0 million, or $0.64 per diluted share.

Operating cash flow for the six months ended March 31, 2009 was $11.8 million compared to $9.4 million for the same period of fiscal 2008. This operating cash flow was used to invest $6.4 million in purchases of property and equipment and repay $5.5 million in net borrowings on the Company's revolving credit facility.

Bill Gay, chairman and chief executive officer, commented, "The economic environment continued to present challenges during the second quarter of fiscal 2009. During both the first and second quarters of fiscal 2009, net sales to many of our domestic and international customers were adversely affected by the decline in world economies. Despite these difficult circumstances, operating cash flow and Adjusted EBITDA remained strong. Gross profit margins remained strong at 53.5% for the second quarter and we were able to reduce inventories by $2.4 million. Additionally, synergies were achieved through reductions in operational and transitional costs related to businesses acquired over the last two years as well as year-over-year cost improvements in many of our selling, general and administrative areas."

Mr. Gay continued, "The uncertainties of the current environment will continue to present ongoing challenges as we strive to serve our customers and grow our business. Our management group is focusing on expanding revenues through customer promotions and product innovation, material sourcing improvements and further reducing controllable costs. Our long term business strategy of selling primarily to the Healthy Foods Channel and growing through add-on acquisitions has served our stakeholders well over the last ten years as a public company and we continue to explore opportunities that will improve profitability and cash flow."

ABOUT NUTRACEUTICAL

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate, from beginning to end, the manufacturing, marketing and distribution of branded nutritional supplement businesses in the natural products industry. We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

We sell branded nutritional supplements and other natural products under the trademarks Solaray(R), VegLife(R), KAL(R), Nature's Life(R), Sunny Green(R), Action Labs(R), Natural Balance(R), NaturalMax(R), bioAllers(R), Herbs for Kids(TM), Natra-Bio(R), NaturalCare(R), Zand(R), Health from the Sun(R), Life-flo(R), Larenim(R), Living Flower Essences(R), Pioneer(R), Thompson(R), Natural Sport(R), Supplement Training Systems(R), Premier One(R), Montana Big Sky(TM), ActiPet(R), FunFresh Foods(TM), Dowd & Rogers(TM), CompliMed(R), AllVia(TM), Oakmont Labs(R), Healthway(R), Body Gold(R), Sayge BioSciences(TM), Monarch Nutraceuticals(TM) and Great Basin Botanicals(TM). Under the name Woodland Publishing(TM), we publish, print and market a line of books and booklets to, among others, book distributors, national retail bookstores and health and natural food stores. We also distribute branded products of certain third parties.

We own neighborhood natural food markets, which operate under the trade names The Real Food Company(TM), Thom's Natural Foods(TM) and Cornucopia Community Market(TM). We also own health food stores, which operate under the trade names Fresh Vitamins(TM) and Granola's(TM).

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 4,000 SKUs, including over 700 SKUs sold internationally. We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although these statements are believed to be reasonable, they are inherently uncertain. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Press Release. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism or civil unrest, (iii) adverse publicity or negative consumer perception regarding nutritional supplements, (iv) changes in government regulations, (v) product liability claims and litigation, (vi) insurance coverage issues, (vii) increased competition or costs, (viii) intellectual property rights of other parties, (ix) the loss of key personnel, (x) disruptions from acquisitions, (xi) issues with obtaining raw materials of adequate quality or quantity, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) changes in general worldwide economic or political conditions, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) litigation generally, and (xvi) other factors indicated from time to time in our SEC reports, copies of which are available upon request from our investor relations group or which may be obtained at the SEC's website (www.sec.gov).

(C) 2009 Nutraceutical Corporation. All rights reserved.


        NUTRACEUTICAL INTERNATIONAL CORPORATION
         CONDENSED CONSOLIDATED BALANCE SHEETS
           (unaudited; dollars in thousands)


                         March 31,   September 30,
                        ----------  --------------
                              2009            2008
    Assets
      Current assets,
       net                 $51,054         $55,577
      Property, plant
       and equipment, net   55,790          52,356
      Goodwill                 332          37,632
      Other non-current
       assets, net          25,869          16,099
                            ------          ------
                          $133,045        $161,664
                          --------        --------

    Liabilities and
     Stockholders' Equity
      Current
       liabilities         $16,187         $19,239
      Long-term
       liabilities          23,776          28,965
      Stockholders'
       equity               93,082         113,460
                            ------         -------
                          $133,045        $161,664
                          --------        --------



                    NUTRACEUTICAL INTERNATIONAL CORPORATION
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           (unaudited; dollars in thousands, except per share data)


                                 Three months ended        Six months ended
                                      March 31,                March 31,
                                 ------------------        ----------------
                                   2009        2008         2009        2008

    Net sales                   $41,957     $44,446      $81,586     $85,532
    Cost of sales                19,517      19,930       37,714      38,703
                                 ------      ------       ------      ------
      Gross profit               22,440      24,516       43,872      46,829
    Operating expenses
      Selling, general and
       administrative            15,713      16,978       31,486      33,606
      Amortization
       of intangible assets         158         170          317         337
      Impairment of goodwill     37,519           -       37,519           -
                                 ------        ----       ------        ----
    Income/(loss) from
     operations                 (30,950)      7,368      (25,450)     12,886
    Interest and other
     (income)/expense, net          264         405          774         785
                                    ---         ---          ---         ---
    Income/(loss) before
     provision/(benefit)
     for income taxes           (31,214)      6,963      (26,224)     12,101
    Provision/(benefit)
     for income taxes            (7,855)      2,611       (5,977)      4,538
                                 ------       -----       ------       -----

    Net income/(loss)          $(23,359)     $4,352     $(20,247)     $7,563
                               --------      ------     --------      ------


    Net income/(loss) per
     common share
      Basic                      $(2.15)      $0.39       $(1.86)      $0.68
      Diluted                     (2.15)       0.39        (1.86)       0.67

    Weighted average
     common shares
     outstanding
      Basic                  10,870,769  11,039,703   10,859,876  11,081,978
      Diluted                10,870,769  11,176,351   10,859,876  11,223,450



                 NUTRACEUTICAL INTERNATIONAL CORPORATION
                         ADJUSTED EBITDA SCHEDULE
                    (unaudited; dollars in thousands)


                                       Three months          Six months
                                      ended March 31,      ended March 31,
                                      ---------------      ---------------
                                      2009       2008      2009       2008

    Net income/(loss)             $(23,359)    $4,352  $(20,247)    $7,563
    Provision/(benefit) for
     income taxes                   (7,855)     2,611    (5,977)     4,538
    Interest and other (income)/
     expense, net (1)                  264        405       774        785
    Depreciation and amortization    1,642      1,430     3,276      2,742
    Impairment of goodwill (2)      37,519          -    37,519          -
                                    ------       ----    ------       ----

    Adjusted EBITDA                 $8,211     $8,798   $15,345    $15,628
                                    ------     ------   -------    -------


    (1)  Includes amortization of deferred financing fees

    (2)  For the three months and six months ended March 31, 2009, a non-cash
         goodwill impairment charge of $37,519 was recorded related to our
         branded and natural food markets reporting units.


'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health
2. Nutraceutical Reports Fiscal 2009 Q1 Results
3. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
4. Nutraceutical Reports 2008 Fiscal Year End Results
5. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
6. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
7. Nutraceuticals could prevent diabetes
8. Nutraceutical Reports Q3 Results
9. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
10. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
11. Berkeley Premium Nutraceuticals Pushes Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology: